Many patients have heard that ACE-inhibitors or ARBs may make COVID-19 disease worse, in the event of infection. They are asking their pharmacists and healthcare providers if it’s safe to stay on ACE-inhibitor or ARB therapy during the COVID-19 pandemic. Do you have the answers you need to answer patients’ questions? Join us for today’s episode of 15 on COVID-19 while we explore potential connections between ACE-inhibitor/ARB therapy and COVID-19 disease. As always, we’ll work to separate fact, hypothesis and fiction to help you navigate the ongoing flood of information about COVID-19.
- Discuss the latest developments related to COVID-19
Activity type: Knowledge-based
Target Audience: Pharmacists and Technicians
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 0.25 contact hour of CPE credit (0.025 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-164-H01-P/T
To obtain credit for completing 15 on COVID-19 03/30/2020, participants will need to watch the archived webinar, complete the assessment, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
Initial release date: March 30, 2020Expiration date: March 30, 2021 - No credit granted after this date
15 on COVID-19 03/30/2020 is an activity for pharmacists and pharamacy technicians developed by the American Pharmacists Association. © 2020 American Pharmacists Association
Daniel Zlott, PharmD, BCOP and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-20-164-H01-P||0.025 CEUs||March 30, 2020 - March 30, 2021|
|ACPE# 0202-0000-20-164-H01-T||0.025 CEUs||March 30, 2020 - March 30, 2021|